Paying Low-Income Smokers to Quit? The Cost-Effectiveness of Incentivizing Tobacco Quit Line Engagement for Medicaid Recipients Who Smoke

Value in Health

Volumn 22, Issue 2, 2019, Pages 177-184

  Mundt, Marlon P ^a   Baker, Timothy B ^a   Fraser, David L ^a   Smith, Stevens S ^a   Piper, Megan E ^a   Fiore, Michael C ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

clinical trials; cost effectiveness; Medicaid; smoking and tobacco

Indexed keywords

AMFEBUTAMONE; CARBON MONOXIDE; NICOTINE; NICOTINE GUM; VARENICLINE;

ABSTINENCE; ADMINISTRATIVE PERSONNEL; ADULT; ARTICLE; BREATH ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; FOLLOW UP; HEALTH CARE SYSTEM; HUMAN; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; MEDICAID; NICOTINE REPLACEMENT THERAPY; PATIENT REFERRAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMOKING CESSATION; URINALYSIS; COST BENEFIT ANALYSIS; ECONOMICS; EPIDEMIOLOGY; HEALTH PROMOTION; MIDDLE AGED; MOTIVATION; POVERTY; PROCEDURES; SMOKING; THERAPY; UNITED STATES;

ADULT; COST-BENEFIT ANALYSIS; FEMALE; FOLLOW-UP STUDIES; HEALTH PROMOTION; HUMANS; MALE; MEDICAID; MIDDLE AGED; MOTIVATION; POVERTY; SMOKERS; SMOKING; SMOKING CESSATION; UNITED STATES;

EID: 85053600748     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2018.08.001     Document Type: Article

References (44)

1. Jamal, A., Phillips, E., Gentzke, A.S., et al. Current cigarette smoking among adults—United States, 2016. MMWR Morb Mortal Wkly Rep 67 (2018), 53–59.
2. Singh, G.K., Williams, S.D., Siahpush, M., Mulhollen, A., Socioeconomic, rural-urban, and racial inequalities in US cancer mortality: Part I, All cancers and lung cancer and Part II, Colorectal, prostate, breast, and cervical cancers. J Cancer Epidemiol, 2011, 2011, 107497.
3. Caleyachetty, A., Lewis, S., McNeill, A., Leonardi-Bee, J., Struggling to make ends meet: exploring pathways to understand why smokers in financial difficulties are less likely to quit successfully. Eur J Public Health 22:Suppl. 1 (2012), 41–48.
4. Kotz, D., West, R., Explaining the social gradient in smoking cessation: it's not in the trying, but in the succeeding. Tob Control 18 (2009), 43–46.
5. Hiscock, R., Judge, K., Bauld, L., Social inequalities in quitting smoking: What factors mediate the relationship between socioeconomic position and smoking cessation?. J Public Health 33 (2011), 39–47.
6. Ku, L., Brantley, E., Bysshe, T., et al. How Medicaid and other public policies affect use of tobacco cessation therapy, United States, 2010–2014. Prev Chronic Dis, 13, 2016, E150.
7. Christiansen, B.A., Reeder, K.M., TerBeek, E.G., et al. Motivating low socioeconomic status smokers to accept evidence-based smoking cessation treatment: a brief intervention for the community agency setting. Nicotine Tob Res 17 (2015), 1002–1011.
8. Ku, L., Bruen, B.K., Steinmetz, E., Bysshe, T., Medicaid tobacco cessation: big gaps remain in efforts to get smokers to quit. Health Aff (Millwood) 35 (2016), 62–70.
9. Hahn, E.J., Rayens, M.K., Chirila, C., et al. Effectiveness of a quit and win contest with a low-income population. Prev Med 39 (2004), 543–550.
10. Okuyemi, K.S., James, A.S., Mayo, M.S., et al. Pathways to health: a cluster randomized trial of nicotine gum and motivational interviewing for smoking cessation in low-income housing. Health Educ Behav 34 (2007), 43–54.
11. Froelicher, E.S., Doolan, D., Yerger, V.B., et al. Combining community participatory research with a randomized clinical trial: the Protecting the Hood Against Tobacco (PHAT) smoking cessation study. Heart Lung 39 (2010), 50–63.
12. Kendzor, D.E., Businelle, M.S., Costello, T.J., et al. Financial strain and smoking cessation among racially/ethnically diverse smokers. Am J Public Health 100 (2010), 702–706.
13. Bryant, J., Bonevski, B., Paul, C., et al. A systematic review and meta-analysis of the effectiveness of behavioural smoking cessation interventions in selected disadvantaged groups. Addiction 106 (2011), 1568–1585.
14. Kendzor, D.E., Reitzel, L.R., Mazas, C.A., et al. Individual- and area-level unemployment influence smoking cessation among African Americans participating in a randomized clinical trial. Soc Sci Med 74 (2012), 1394–1401.
15. Lasser, K.E., Quintiliani, L.M., Truong, V., et al. Effect of patient navigation and financial incentives on smoking cessation among primary care patients at an urban safety-net hospital: a randomized clinical trial. JAMA Intern Med 177 (2017), 1798–1807.
16. Volpp, K.G., Troxel, A.B., Pauly, M.V., et al. A randomized, controlled trial of financial incentives for smoking cessation. N Engl J Med 360 (2009), 699–709.
17. Businelle, M.S., Kendzor, D.E., Kesh, A., et al. Small financial incentives increase smoking cessation in homeless smokers: a pilot study. Addict Behav 39 (2014), 717–720.
18. Halpern, S.D., French, B., Small, D.S., et al. Randomized trial of four financial-incentive programs for smoking cessation. N Engl J Med 372 (2015), 2108–2117.
19. Etter, J.F., Schmid, F., Effects of large financial incentives for long-term smoking cessation: a randomized trial. J Am Coll Cardiol 68 (2016), 777–785.
20. Lopez-Nunez, C., Alonso-Perez, F., Pedrosa, I., Secades-Villa, R., Cost-effectiveness of a voucher-based intervention for smoking cessation. Am J Drug Alcohol Abuse 42 (2016), 296–305.
21. Kendzor, D.E., Businelle, M.S., Poonawalla, I.B., et al. Financial incentives for abstinence among socioeconomically disadvantaged individuals in smoking cessation treatment. Am J Public Health 105 (2015), 1198–1205.
22. Cahill, K., Perera, R., Competitions and incentives for smoking cessation. Cochrane Database Syst Rev, 2011 CD004307.
23. Dallery, J., Raiff, B.R., Kim, S.J., et al. Nationwide access to an internet-based contingency management intervention to promote smoking cessation: a randomized controlled trial. Addiction 112 (2017), 875–883.
24. Sigmon, S.C., Patrick, M.E., The use of financial incentives in promoting smoking cessation. Prev Med 55:Suppl (2012), S24–S32.
25. Ladapo, J.A., Prochaska, J.J., Paying smokers to quit: Does it work? Should we do it?. J Am Coll Cardiol 68 (2016), 786–788.
26. Fiore, M.C., Jaen, C.R., Baker, T.B., et al. A clinical practice guideline for treating tobacco use and dependence: 2008 update—a US Public Health Service report. Am J Prev Med 35 (2008), 158–176.
27. Fraser, D.L., Fiore, M.C., Kobinsky, K., et al. A randomized trial of incentives for smoking treatment in Medicaid members. Am J Prev Med 53 (2017), 754–763.
28. Bock, B.C., Papandonatos, G.D., de Dios, M.A., et al. Tobacco cessation among low-income smokers: motivational enhancement and nicotine patch treatment. Nicotine Tob Res 16 (2014), 413–422.
29. Cummings, K.M., Hyland, A., Impact of nicotine replacement therapy on smoking behavior. Annu Rev Public Health 26 (2005), 583–599.
30. Murphy, J.M., Mahoney, M.C., Hyland, A.J., et al. Disparity in the use of smoking cessation pharmacotherapy among Medicaid and general population smokers. J Public Health Manag Pract 11 (2005), 341–345.
31. Ryder, H.F., McDonough, C., Tosteson, A.N., Lurie, J.D., Decision analysis and cost-effectiveness analysis. Semin Spine Surg 21 (2009), 216–222.
32. Neumann, P.J., Sanders, G.D., Russell, L.B., et al. Cost-Effectiveness in Health and Medicine, 2nd ed, 2016, Oxford University Press, New York, NY.
33. Medicaid Services HHS. Drug pricing and payment (National Average Drug Acquisition Cost). Secondary drug pricing and payment (National Average Drug Acquisition Cost). 2016. Available from: https://www.data.medicaid.gov/Drug-Pricing-and-Payment/NADAC-as-of-2016-01-06/p8pu-f52w. [Accessed May 3, 2017].
34. Sanders, G.D., Neumann, P.J., Basu, A., et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second Panel on Cost-Effectiveness in Health and Medicine. JAMA 316 (2016), 1093–1103.
35. Briggs, A.H., Mooney, C.Z., Wonderling, D.E., Constructing confidence intervals for cost-effectiveness ratios: an evaluation of parametric and non-parametric techniques using Monte Carlo simulation. Stat Med 18 (1999), 3245–3262.
36. Kim, S., Overview of cotinine cutoff values for smoking status classification. Int J Environ Res Public Health, 13, 2016, pii E1236.
37. SRNT Subcommittee on Biochemical Verification. Biochemical verification of tobacco use and cessation. Nicotine Tob Res 4 (2002), 149–159.
38. Marrone, G.F., Paulpillai, M., Evans, R.J., et al. Breath carbon monoxide and semiquantitative saliva cotinine as biomarkers for smoking. Hum Psychopharmacol 25 (2010), 80–83.
39. Andersson, M.F., Moller, A.M., Assessment of carbon monoxide values in smokers: a comparison of carbon monoxide in expired air and carboxyhaemoglobin in arterial blood. Eur J Anaesthesiol 27 (2010), 812–818.
40. Javitz, H.S., Zbikowski, S.M., Deprey, M., et al. Cost-effectiveness of varenicline and three different behavioral treatment formats for smoking cessation. Transl Behav Med 1 (2011), 182–190.
41. Torrance, G.W., Measurement of health state utilities for economic appraisal—a review. J Health Econ 5 (1986), 1–30.
42. Jha, P., Ramasundarahettige, C., Landsman, V., et al. 21st-century hazards of smoking and benefits of cessation in the United States. N Engl J Med 368 (2013), 341–350.
43. Neumann, P.J., Cohen, J.T., Weinstein, M.C., Updating cost-effectiveness—the curious resilience of the $50,000-per-QALY threshold. N Engl J Med 371 (2014), 796–797.
44. Braithwaite, R.S., Meltzer, D.O., King, J.T., et al. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?. Med Care 46 (2008), 349–356.